» Articles » PMID: 26690230

Application of Oral Fluid Assays in Support of Mumps, Rubella and Varicella Control Programs

Overview
Date 2015 Dec 23
PMID 26690230
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Detection of specific viral antibody or nucleic acid produced by infection or immunization, using oral fluid samples, offers increased potential for wider population uptake compared to blood sampling. This methodology is well established for the control of HIV and measles infections, but can also be applied to the control of other vaccine preventable infections, and this review describes the application of oral fluid assays in support of mumps, rubella and varicella national immunization programs. In England and Wales individuals with suspected mumps or rubella, based on clinical presentation, can have an oral fluid swab sample taken for case confirmation. Universal varicella immunization of children has led to a drastic reduction of chickenpox in those countries where it is used; however, in England and Wales such a policy has not been instigated. Consequently, in England and Wales most children have had chickenpox by age 10 years; however, small, but significant, numbers of adults remain susceptible. Targeted varicella zoster virus (VZV) immunization of susceptible adolescents offers the potential to reduce the pool of susceptible adults and oral fluid determination of VZV immunity in adolescents is a potential means of identifying susceptible individuals in need of VZV vaccination. The main application of oral fluid testing is in those circumstances where blood sampling is deemed not necessary, or is undesirable, and when the documented sensitivity and specificity of the oral fluid assay methodology to be used is considered sufficient for the purpose intended.

Citing Articles

SARS Antibody Testing in Children: Development of Oral Fluid Assays for IgG Measurements.

Hoschler K, Ijaz S, Andrews N, Ho S, Dicks S, Jegatheesan K Microbiol Spectr. 2022; 10(1):e0078621.

PMID: 34985331 PMC: 8729769. DOI: 10.1128/spectrum.00786-21.


Applicability of oral fluid samples for tracking hepatitis B virus mutations, genotyping, and phylogenetic analysis.

Portilho M, Bezerra C, Mendonca A, Marques V, Cancella Nabuco L, Villela-Nogueira C Arch Virol. 2021; 166(9):2435-2442.

PMID: 34146173 DOI: 10.1007/s00705-021-05122-x.


Using the Past to Maximize the Success Probability of Future Anti-Viral Vaccines.

Serwer P Vaccines (Basel). 2020; 8(4).

PMID: 33019507 PMC: 7712378. DOI: 10.3390/vaccines8040566.

References
1.
Williams V, Gershon A, Brunell P . Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence. J Infect Dis. 1974; 130(6):669-72. DOI: 10.1093/infdis/130.6.669. View

2.
Manikkavasagan G, Bukasa A, Brown K, Cohen B, Ramsay M . Oral fluid testing during 10 years of rubella elimination, England and Wales. Emerg Infect Dis. 2010; 16(10):1532-8. PMC: 3294398. DOI: 10.3201/eid1610.100560. View

3.
Enders M, Rist B, Enders G . [Frequency of spontaneous abortion and premature birth after acute mumps infection in pregnancy]. Gynakol Geburtshilfliche Rundsch. 2005; 45(1):39-43. DOI: 10.1159/000081715. View

4.
Koturoglu G, Kurugol Z, Turkoglu E . Seroepidemiology of varicella-zoster virus and reliability of varicella history in Turkish children, adolescents and adults. Paediatr Perinat Epidemiol. 2011; 25(4):388-93. DOI: 10.1111/j.1365-3016.2010.01180.x. View

5.
Miller E, Waight P, Gay N, Ramsay M, Vurdien J, Morgan-Capner P . The epidemiology of rubella in England and Wales before and after the 1994 measles and rubella vaccination campaign: fourth joint report from the PHLS and the National Congenital Rubella Surveillance Programme. Commun Dis Rep CDR Rev. 1997; 7(2):R26-32. View